期刊文献+

喜树碱类药物的现代研究进展 被引量:6

Research and Application of Camptothecins
下载PDF
导出
摘要 喜树碱类药物是用于临床的拓扑异构酶Ⅰ抑制剂,是继紫杉醇后又一个很有发展前途的抗癌药,已成为目前抗癌药物中研究的热点。介绍近年来国内外对喜树碱类药物剂型和其前体药物研究方面的进展情况。 Currently, camptothecins are a class of topoisomerase-Ⅰ inhibitor that has been used in clinical practice. It is a kind of anticancer drug with great prospect after taxinol and is becoming the hot research topic of anticancer drugs. The studies and applications of camptothecins' preparation and their prodrug are summarized in this paper.
作者 姜琦 王海翔
出处 《药学进展》 CAS 2007年第9期408-412,共5页 Progress in Pharmaceutical Sciences
关键词 喜树碱 抗癌 剂型 前体药物 Camptothecin Anticancer Preparation Prodmg
  • 相关文献

参考文献31

二级参考文献124

  • 1顾德辛.抗肿瘤药喜树碱及其类似物的研究开发[J].中国医药情报,1995,1(6):340-344. 被引量:3
  • 2[1]Rothenberg ML.Efficacy and toxicity of irinotecan in patients with colorectal cancer[J].Semin Oncol,1998,25(5 suppl 11):39.
  • 3[2]Miya T, Fujikawa R, Fukushima J,et al.Bradycardia induced by irinotecan:a case report[J].Jpn J Clin Oncol,1998,28(11):709.
  • 4[3]Rivory LP,Chatelut E,Canal P,et al. Kinetics of the in vivo interconversion of the carboxylate and lactone for-ms of irinotecan(CPT-11)and of its metabolite SN-38 in patients[J].Cancer Res,1994,54(24):6 330.
  • 5[4]Cunningham D,Pyrhonen S,James RD,et al.Random-ised trial of irinotecan plus supportive care versus sup-portive care alone after fluorouracil failure for patients with metastatic colorectal cancer[J].Lancet,1998,352(9138):1 413.
  • 6[5]Rougier P,Van Cutsem E,Bajetta E,et al.Randomised trial of irinotecan versus fluorouracil by continuous in-fusion after fluorouracil failure in patients with metas-tatic colorectal cancer[J].Lancet,1998,352(9138):1 407.
  • 7[6]Rowinsky EK,Baker SD,Burks K,et al.High-dose to-potecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer:a phaseⅡ and pharmacodynamic study[J].Ann Oncol,1998,9(2):173.
  • 8[7]Perez Soler R,Fossella FV,Glisson BS,et al.PhaseⅡstudy of topotecan in patients with advanced non-sm-all-cell lung cancer previously untreated with chemo-therapy[J].J Clin Oncol,1996,14(2):503.
  • 9[8]Gerrits CJ,Burris H,Schellens JH,et al.Oral topotecan given once or twice daily for ten days:a phase I pharmacology study in adult patients with solid tumors[J].Clin Cancer Res,1998,4(5):1 153.
  • 10[9]Perez Soler R,Glisson BS,Lee JS,et al.Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan[J].J Clin Oncol,1996,14(10):2 785.

共引文献264

同被引文献74

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部